Lilly to Present Phase II Rheumatoid Arthritis and Biomarker Data at ACR For …
INDIANAPOLIS, Nov. 9, 2012 — /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will present Phase II data in rheumatoid arthritis (RA) for two of its investigational autoimmune medicines at the annual meeting of the American College of Rheumatology …

Full News here – Read more on Sacramento Bee